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The objective of the present research was to determine the prevalence of oral manifestations in an HIV infected population from
south India and evaluate their association with HIV viral load and CD4/CD8 ratio. Intraoral examination of 103 patients, whose
CD4/CD8 ratio was available, were conducted. HIV viral loads were available for thirty patients only. The prevalence of oral
manifestations was 80.6% (83/103). The most common oromucosal lesion was erythematous candidiasis (EC) (38.8%) followed
by melanotic hyperpigmentation (35.9%). Patients having any oral manifestation had a mean CD4/CD8 ratio of 0.24. EC had
positive predictive value of 85.0% for CD4/CD8 ratio <0.30. The prevalence of oral manifestations in patients taking ART was
lesser (78.6%) as compared to patients not taking ART (82%). Patients having any oral manifestation had a higher HIV viral load
as compared to patients not having any oral manifestations (P<0.05). Pseudomembranous candidiasis (PC) was signiﬁcantly
associated with higher HIV viral loads (>20,000copies/mL) (P<0.05). Patients having EC had 4 times greater chance of having
CD4/CD8 ratio <0.30. PC can be considered as a marker of immune suppression (HIV viral load >20,000copies/mL).
1.Introduction
1.8 million people died in 2009 due to AIDS-related causes,
andanestimated2.6millionpeoplewerenewlyinfectedwith
HIV in world [1]. India carries the third largest number of
HIV infected patients in the world after South Africa and
Nigeria [1]. HIV infection causes depletion of CD4 cells
in peripheral blood and lymphoid tissue causing CD8 cell
dysfunction [2]. Quantitation of CD4 helper lymphocytes
is thus essential in the staging and monitoring of patients
infected with HIV. Throughout the course of disease, the
total T-cell levels remain fairly constant despite a fall in CD4
cell count due to compensatory rise in CD8 cells. Absolute
CD4 counts are known to be inherently inconsistent and
thereforecouldbemisleading[3].ThereforetheratioofCD4
cell to CD8 cells is a signiﬁcant measure which is of greater
magnitudeascomparedtoabsoluteCD4cellcountofdisease
progressioninHIV-infectedsubjects[3].PlasmaHIV-1RNA
levels have been shown to be a strong predictor of rapid
progressiontoAIDSafterseroconversionthatisindependent
of CD4+ counts [4]. High viral load is currently considered
to be one of the main indicators of HIV-induced immune
deterioration.
SincetheonsetofHIV/AIDSepidemic,theoralcavityhas
played a key role in helping to deﬁne the natural history of
HIV/AIDS. The occurrence of oral manifestations is favored
by immune deterioration. Few studies have evaluated the
relationship of CD4/CD8 ratio with oral manifestations
[5–8]. High CD8 lymphocytosis and low CD4/CD8 ratio
have also been associated with oral candidiasis (OC) [5, 7].
Studies from western countries have also shown association
of oral manifestations with higher HIV viral load [9–12].
However till date no Asian study has attempted to assess
the relationship between oral manifestations with CD4/CD8
ratio and HIV viral load. The possible reasons for absence of
studies related to HIV viral load conducted in Asia could be
ﬁnancial and resource constraints.
In the present study, a group of HIV patients from
south Indian population were analyzed to identify possible
associationoforalmanifestationswithCD4/CD8countratio2 International Journal of Dentistry
and HIV viral load and to evaluate the diagnostic utility
of correlating main oral manifestations for low CD4/CD8
ratios(<0.30) using positive predictive value (PPV), negative
predictive value (NPV).
2.SubjectsandMethods
The cross-sectional study was conducted over 1-year period
between January 2005 and December 2005 under the
approval of IREC (institutional research ethical committee).
Written informed consents were obtained from partici-
pants (patients). One hundred and three HIV positive
patients were screened and were included in study. Their
respective CD4/CD8 ratio was available within 2 weeks
of oral examination. All 103 patients were diagnosed as
HIV-antibody positive by enzyme-linked immunosorbent
assay (ELISA)-HIV. Three separate positive ELISA tests were
considered conﬁrmatory. The patients were selected from
our patient department of infectious diseases unit at Attavar
hospital, Mangalore and hospitalized patients of Kasturba
hospital, Manipal. Sociodemographic data were obtained
using structured questionnaire. A patient was considered as
smoker if there was past or current history of smoking of at
least 1 cigarette/beedi a day for at least 1 year. Similarly an
assessment of consumption of alcohol (any type) was also
donebyaskingpatientabouthis/hercurrentconsumptionof
alcohol (more than 30 grams) at least once a week for 1year.
Clinical history was obtained from patient’s medical
records. Absolute CD4+ and absolute CD8 lymphocyte
counts were performed using ﬂow cytometry (SRL, Ran-
baxy laboratories, Mumbai) within 2 week of the oral
examination. Patients according to CD4/CD8 ratio were
clustered into 3 groups: group I (0.01–0.30), group II
(0.31–0.60), and group III (>0.60). HIV viral load was
also documented from 30 patients among the study sample
of 103 patients and was subsequently constellated in 2
groups (<20,000copies/mL and >20,000copies/mL). Oral
manifestations were diagnosed according to presumptive
criteria of EEC-clearinghouse classiﬁcation (1993) [13]. A
single examiner trained in oral medicine (G.S.) examined
and recorded all oromucosal lesions.
3.StatisticalAnalysis
Statistical analysis was done using SPSS software version
11. Associations between subject variable and each type of
oral lesion were analyzed using chi-square test. Odds ratio
and 95% conﬁdence interval were used in logistic regression
analysis for association between oral manifestations and
CD4/CD8 ratio within group I. Mann-Whitney U test
was used for diﬀerences between mean values of group of
patients. PPV and NPV of individual oral manifestations for
low CD4+/CD8 ratio were calculated. The probability that
the patient has CD4/CD8 ratio <0.30 when a speciﬁc oral
manifestation is present is called as positive predictive value
(PPV). Negative predictive value (NPV) is reported as the
possibility that the patient’s CD4/CD8 ratio >0.30 when a
speciﬁc oral manifestation is absent. Statistical signiﬁcance
was set at P ≤ 0.05.
Table 1: Demographics and laboratory parameters of study cohort.
Variable
Total no. of
patients
(n −103)
No. of patients
with oral
manifestations
(83/103)
Gender
Male 70 58 (82.9%)
Female 33 25 (75.8%)
Mode of transmission
Heterosexual mode 101 81 (80.1%)
Homosexual mode 2 2 (100%)
Antiretroviral therapy
Yes 42 33 (78.6%)
No 61 50 (82.0%)
Smoker
Yes 32 29 (90.6%)
No 71 54 (76.1%)
Alcohol consumption
Yes 48 39 (81.3%)
No 55 44 (80%)
Absolute CD4/CD8 ratio staging
Group I (0.01–0.30) 69 61 (88.4%)
Group II (0.31–0.60) 28 18 (64.2%)
Group III (>0.60) 6 04 (66.7%)
4. Results
The demographic distribution of 103 patients (age range 24–
68years;meanage37.1years;70males,33females)consisted
of all south Indians. Social demographics, their oral habits,
usage of antiretroviral therapy and laboratory parameters of
thestudycohortcanbeobservedinTable 1.Amongthestudy
population 101 patients (98.3%) had CD4/CD8 ratio less
than 1 (normal range 0.03–1.61) which is suggestive of an
advanced immunosuppression in this study (P value <. 05;
chi-square test). 32 (31.1%) patients were smokers and 48
(46.6%) patients were alcoholics.
The mean absolute CD4 lymphocyte count among
low CD4/CD8 ratio (group I) was 163.43cells/mm3 (S.D
143.59), while patients within group II had mean value of
325.00cells/mm3 (S.D 167.46) and patients within group
III had 502.33cells/mm3 (S.D 290). When comparing CD4
lymphocyte counts to CD4/CD8 ratio among diﬀerent
groups, low-ratio patients had signiﬁcant diﬀerences from
those patients who had higher ratios (P<. 001). Mean
CD4/CD8 ratio of entire study cohort was found to be
0.26 {standard deviation (S.D)—0.22}. The mean abso-
lute CD4 and CD8 counts of study cohort were 228.82
and 988.6cells/mm3, respectively. Higher HIV viral load
>20,000copies/mL was seen in patients below CD4/CD8
ratio <0.30. (Table 2).
Oral manifestations were present in 83 (80.6%) patients.
Oral manifestations were also clustered according to varying
CD4/CD8 ratios corresponding, respectively, to groups IInternational Journal of Dentistry 3
Table 2: Absolute mean CD4 and CD8 counts along with mean CD4/CD8 ratio of study cohort.
Clustering of patients according
to CD4/CD8 ratio
Mean absolute CD4 count
(cells/mm3)
Mean absolute CD8 count
(cells/mm3) Mean CD4/CD8 ratio
Group I (0.01–0.30) (n −69) 163.43 1053.1 0.15
Group II (0.31–0.60) (n−28) 325.00 889.1 0.39
Group III (>0.60) (n −6) 502.33 659.8 0.93
Total no. of patients (n −103) 228.82 988.6 0.26
Table 3: Oral manifestations in relation to CD4/CD8 ratio.
Oral manifestations Group I Group II Group III Total
n −69 n −28 n −6( n −103)
Any oral manifestation∗ 61 (88.4%) 18 (64.3%) 4 (66.7%) 83 (80.6%)
Erythematous candidiasis (EC) 34 (49.3%) 5 (17.9%) 1 (16.7%) 40 (38.8%)
Pseudomembranous candidiasis (PC) 7 (10.1%) 2 (7.1%) — 9 (8.7%)
Hyperpigmentation 28 (40.6%) 8 (28.6%) 1 (16.7%) 37 (35.9%)
Oral hairy leukoplakia (OHL) 14 (20.3%) 3 (10.7%) 1 (16.7%) 18 (17.5%)
Necrotizing ulcerative gingivitis (NUG) 8 (11.6%) 2 (7.1%) — 10 (9.7%)
Necrotizing ulcerative periodontitis (NUP) 3 (4.3%) — 1 (16.7%) 4 (3.9%)
Linear gingival erythema (LGE) 12 (17.4%) 2 (7.4%) — 14 (13.6%)
Xerostomia 26 (37.7%) 5 (17.9%) 2 (33.3%) 33 (32.0%)
Angular cheilitis (AC) 6 (8.7%) — — 6 (5.8%)
Apthous ulcers 4 (5.7%) 1 (3.6%) — 5 (4.9%)
Exfoliative cheilitis 2 (2.8%) — — 2 (1.9%)
Hyperplastic candidiasis 1 (1.4%) 1 (3.6%) — 2 (1.9%)
Herpes zoster 1 (1.4%) 1 (3.6%) — 2 (1.9%)
∗Many patients had more than one oral manifestation.
(0.01–0.30), II (0.31–0.60), and III (>0.60). Erythematous
candidiasis (EC) (49.3%), melanotic hyperpigmentation
(40.6%), and xerostomia (37.7%) were common oral ﬁnd-
ings within group I, whereas within group II melanotic
hyperpigmentation (28.6%) followed by EC (17.9%) were
more frequent oral manifestations. Overall, EC (38.8%)
was most common ﬁnding followed by melanotic hyperpig-
mentation (35.9%), xerostomia (32.0%), oral hairy leuko-
plakia (OHL) (17.5%), and linear gingival erythema (LGE)
(Table 3).
Current mean CD4/CD8 ratios for groups with and
without oral manifestations are given in Table 4.T h em e a n
absolute CD4 count for the study cohort with presence
of any oral manifestation was 196.18cells/mm3,a n dm e a n
CD4/CD8 ratio for the study cohort was 0.24 (S.D 0.22). The
lowest mean CD4/CD8 ratio of 0.16 among individual oral
manifestations was found for pseudomembranous candidi-
asis (PC) (mean absolute CD4 count—126.78cells/mm3).
Mann-Whitney U test revealed a statistically signiﬁcant
diﬀerence between mean values of group when any oral
manifestation was present (P<0.05) as compared to when
oral manifestations were absent. Among individual oral
manifestations highly statistical signiﬁcant diﬀerences were
f o u n df o rE Ca n dP C[ P<0.05]. No statistically signiﬁcant
diﬀerences were found for xerostomia, hyperpigmentation,
and OHL.
PPV and NPV for association of speciﬁc oral manifes-
tations when compared with CD4/CD8 ratio within group
Iw e r ec a l c u l a t e d( Table 5). The PPVs for EC, PC, OHL
and melanotic hyperpigmentation were 85%, 77.8%, 77.8%,
and 75.7%, respectively. The NPVs for EC, PC, OHL, and
melanotic hyperpigmentation were 44.4%, 34.3%, 35.3%,
and 37.9%, respectively. Multivariate regression analysis was
done to show odds ratio and 95% conﬁdence interval for all
oral manifestations with low CD4/CD8 ratios (<0.30). EC
had a high odds ratio of 4.530 for low CD4/CD8 ratio. For
other oral manifestations, no statistical signiﬁcance could be
reached (Table 5).
Subdistributionofpatients(30/103)accordingtocluster-
ing of HIV viral loads is given in Table 6. The most common
oral manifestation among the HIV viral load subpopulation
(n−30)wasEC(40.0%),xerostomia(30.0%),andmelanotic
hyperpigmentation (26.6%). 16 Patients had HIV viral
load >20,000copies/mL and remaining had HIV viral load
<20,000copies/mL. All the patients (16/16; 100%) having
HIV viral load >20,000copies/mL had some type of oral
manifestation (statistically signiﬁcant; P<0.05). Among
individual oral manifestations, PC was seen more frequently
in patients with viral loads greater than 20,000copies/mL
(P< 0.05).
Table 7 gives the comparison of oral manifestations
between patients on ART (n − 42) and patients not on ART4 International Journal of Dentistry
Table 4: Mean CD4/CD8 ratio and their association with presence or absence of oral manifestations.
Oral manifestations
(OM)
Mean absolute CD4 count
when respective OM present
(cells/mm3)
Mean CD4/CD8 ratio of
group when respective OM
present
Mean CD4/CD8 ratio of
group when respective OM
absent
ZP value
Any oral manifestation 196.18 0.24 (S.D—0.23) 0.35 (S.D—0.17) 3.2 .01a
EC 147.18 0.18 (S.D—0.12) 0.32 (S.D—0.26) 3.73 .00a
PC 126.78 0.16 (S.D—0.15) 0.27 (S.D—0.23) 1.8 .05a
OHL 149.39 0.26 (S.D—0.23) 0.26 (S.D—0.22) .08 .93b
Hyperpigmentation 192.27 0.23 (S.D—0.26) 0.28 (S.D—0.20) 1.7 .08b
Xerostomia 195.7 0.22 (S.D—0.17) 0.29 (S.D—0.24) 1.8 .07b
S.D: Standard deviation.
aStatistically signiﬁcant.
bNot statistically signiﬁcant.
Table 5: Predictive values of oral manifestations for CD4/CD8 ratio <0.30.
Oral manifestation PPV NPV Odds ratio 95% CI P value
EC 85.0% 44.4% 4.53 1.66–12.32 .003a
OHL 77.8% 35.3% 1.90 0.57–6.31 .290b
Hyperpigmentation 75.7% 37.9% 1.98 0.77–4.66 .164b
Xerostomia 78.8% 38.6% 2.33 0.89–6.11 .085b
NUG 80.0% 34.4% .477 0.09–2.37 .366b
PC 77.8% 34.0% 1.80 0.35–9.91 .477b
LGE 85.7% 36.0% 3.36 0.70–16.00 .127b
PPV: Positive predictive value, NPV: Negative predictive value.
aStatistically signiﬁcant.
bNot statistically signiﬁcant.
(n − 61). A reduced prevalence of oral manifestations in
patients on ART (33/42; 78.6%) was observed as compared
to those patients not on ART (50/61; 82%). The prevalence
of melanotic hyperpigmentation was 40.5% followed by
EC (35.7%), xerostomia (28.6%), angular cheilitis (11.9%),
OHL (9.5%), and PC (7.1%) in patients on ART. No
statistical signiﬁcance could be observed for any individual
oral manifestations for patients on ART.
5. Discussion
Since the beginning of AIDS epidemic, developing countries
have experienced diﬃculties in implementing appropri-
ate, inexpensive, and eﬃcient HIV laboratory diagnostic
techniques to aid in the epidemiological assessment and
control of HIV infection. Asian and the African countries
together house 95% of global HIV burden. Studies have
been conducted in Asia for association of oral manifestations
with absolute CD4 lymphocyte counts [14–16]. However, on
doing a comprehensive literature search we could not ﬁnd
any Asian study for association of oral manifestations with
CD4/CD8 ratio and HIV viral load. Hence an attempt was
made in this study for correlation of oral manifestations with
HIV viral load and CD4/CD8 ratio for immune suppression.
The prevalence of oral manifestation in our study was
80.6%. This ﬁnding was similar to studies conducted in
V e n e z u e l a( 8 5 % )[ 9], Thailand (77.0%) [16], and Nigeria
(84.0%) [17]. In another Indian study the prevalence of
oral manifestations were seen in 72.3% patients [15]. 82.9%
(58/70) males had oral manifestations as compared to
75.8% (25/33) females (Table 1). No statistically signiﬁcant
diﬀerences were seen in oral manifestations in either gender.
This ﬁnding is similar to other studies [15, 18]w h e r e
males had more oral manifestations. Oral manifestations
were seen more in smokers (90.6%; 29/32) as compared
to oral manifestations in nonsmokers (76.1%; 54/71), but
without statistical signiﬁcance (P>. 05). Smoking may
produce particulate matter, noxious chemicals, and heat that
can modify more local factors. Oral manifestations were
equally prevalent in alcoholics (81.3%; 39/48) as well as
nonalcoholics (80%; 44/55). No statistical signiﬁcance was
also observed for individual oral manifestations with gender,
smoking and alcohol (P>. 05).
Since myriad factors can aﬀect T-cell subsets, changes in
CD4+ T cells and CD8+ T cells reﬂected through CD4/CD8
ratioshouldbeinvestigatedoveratimeframe,preferablya3–
6month period to assess the immune status of patient. The
clinicalsigniﬁcanceofCD4/CD8 ratioandHIVviralloadare
well established for HIV disease progression, but as to date,
no consensus has been reached in scientiﬁc literature as to
what comprises the standard grouping for CD4/CD8 ratios
and HIV viral load.
The prevalence of EC was 38.8% (Table 3) that was
comparable to studies conducted by Campo et al. 2002
(37.8%) [10] and Nittayananta et al. (40%) [18]. Among
candidal infections the most common ﬁnding was EC
(38.8%) followed by PC (8.7%), angular cheilitis (AC)International Journal of Dentistry 5
Table 6: Comparison of oral manifestations with respect to HIV viral load subpopulation.
Oral manifestations HIV viral load <20,000copies/mL HIV viral load >20,000copies/mL Total P value
n −14 n −16 n − 30
Any oral manifestation 9 (64.3%) 16 (100%) 25 (83.3%) .00a
EC 2 (14.2%) 10 (62.5%) 12 (40.0%) .07b
Hyperpigmentation 3 (21.4%) 5 (31.2%) 8 (26.6%) .54b
Xerostomia 2 (14.2%) 7 (43.8%) 9 (30.0%) .07b
OHL 2 (14.2%) 2 (12.5%) 4 (13.3%) .88b
PC — 5 (31.2%) 5 (16.6%) .02a
AC — 2 (12.5%) 2 (6.6%) —
LGE 2 (14.2%) — 2 (6.6%) —
NUG — 2 (12.5%) 2 (6.6%) —
Hyperplastic candidiasis — 1 (6.2%) 1 (3.3%) —
aStatistically signiﬁcant.
bNot statistically signiﬁcant.
Table 7: Comparison of oral manifestations with respect to antiretroviral therapy.
Oral manifestation (OM) Patients with OM on antiretroviral therapy (ART) Patients with OM not on ART P value
n −42 n −61
Any oral manifestation 33 (78.6%) 50 (82%) .66a
EC 15 (35.7%) 25 (41.0%) .59a
OHL 4 (9.5%) 14 (23.0%) .07a
AC 2 (4.8%) 4 (6.6%) .70a
PC 3 (7.1%) 6 (9.8%) .63a
Hyperpigmentation 17 (40.5%) 20 (32.8%) .42a
Xerostomia 12 (28.6%) 21 (34.4%) .53a
LGE 5 (11.9%) 9 (14.8%) .67a
NUG 5 (11.9%) 5 (8.2%) .53a
NUP 1 (2.4%) 3 (4.9%) .51a
aNot statistically signiﬁcant.
(5.8%), and hyperplastic candidiasis (1.9%). Prognostic
signiﬁcance for both EC and PC has been reported to be
similar by two longitudinal studies by Dodd et al. 1991 and
Nielsen et al. 1994 [19, 20]. Fonseca et al. 2000 correlated
oral manifestations with CD4/CD8 ratio in 51 HIV positive
children and concluded that patients with CD4/CD8 ratio
<0 . 5t ob em o r es u s c e p t i b l et oP Ca n dE C[ 21].
A higher frequency for EC was found in our patients
within group I (49.3%), as compared to group II (17.9%)
and group III (16.7%). This diﬀerence was found to be
statistically signiﬁcant (P<0.05; chi-square test of associa-
tion). The decreasing prevalence of EC with lower CD4/CD8
ratio suggests deteriorating immune system and accelerated
destruction of lymphocytes [9]. EC has been found to occur
more frequently in patients with low CD4/CD8 ratio [5, 22,
23]. However, for other oral manifestations no signiﬁcant
diﬀerences were observed.
Mean values of CD4/CD8 ratio for EC were 0.18 which
was lower than 0.40 in another study [5] that also concluded
that when CD4/CD8 ratio is less than 0.5 in patients with
EC, it appears to be of prognostic signiﬁcance as 80% of
patients developed AIDS at a median of 3months. This
ﬁnding suggests the magnitude of utility of diagnosis of EC.
However,thisconclusioncanbeconﬁrmedafterlongitudinal
studies of large sample size are conducted and use of
stringent deﬁnitive criteria as there is a concern for potential
misdiagnosis in following presumptive criteria. However due
to lack of resources and practical feasibility, epidemiological
studies throughout the world have followed presumptive
criteria for diagnosis of oral manifestations in HIV/AIDS
infected population.
The mean CD4/CD8 ratio for any oral manifestation
was 0.24 ± 0.23 which signiﬁes that presence of any single
oral manifestation increases probability (PPV—73.5%) of
a patient having lowered immune status as compared
to patients not having any oral manifestation (Table 4).
Diﬀerence of mean values was also signiﬁcantly diﬀer-
ent (P<0.05). This emphasizes the need for careful
oral examination as oral manifestations can act as an
indicator for immune suppression, especially in resources
deﬁcient clinical settings and also in probable diagnosis
of new cases of HIV. An early and timely diagnosis will
help in improved treatment planning and prognosis of
patients.6 International Journal of Dentistry
PPVs for oral manifestations to low CD4/CD8 ratio
<0.30 were in a high range from 75.7% for melan-
otic hyperpigmentation to 85.7% for linear gingival ery-
thema (LGE). Multivariate regression analysis showed that
patients with EC had 4 times greater chance of having
CD4/CD8 ratio <0.30 {OR—4.728 (1.816–12.313); P =
0.001 and OR—4.530 (1.667—12.323); P = 0.003} as com-
pared to patients with absence of EC. No other statistically
signiﬁcant ﬁndings for oral manifestations were found
(Table 5). This ﬁnding is signiﬁcant as EC can be considered
as a clinical marker of AIDS for CD4/CD8 ratio <0.30 and
hence ART can be instituted.
Oral hairy leukoplakia (OHL) was observed in 18
(17.5%) patients. This ﬁgure is slightly higher to studies
conductedbyLaurencoandFigueiredo(11.8%)andPedreira
et al. (9%) [24, 25]. Reichart et al. [6] found the mean
CD4/CD8 ratio as 0.24 with range 0.04–1.0, which is almost
similar to our study (0.26). However, we could not ﬁnd
any statistically signiﬁcant diﬀerences for OHL with low
CD4/CD8 ratio. There is no consensus for relationship of
OHL with low absolute CD4+ counts as conﬂicting results of
its association have been found [9, 11]. More studies need to
bedone,especiallyinAsianandAfricancountries,toconﬁrm
whether OHL can be associated with low CD4/CD8 ratio.
HIV viral load is known to have better predictive value
than absolute CD4 cell count of long-term clinical outcome
while CD4+ lymphocyte count is more useful for short-
term clinical outcome [26, 27]. Patients with the oral
manifestations had a greater HIV viral load (P<0.05),
a ﬁnding corroborated in other studies also [9, 10, 12]
(Table 5). However, Gaitan-Cepeda et al. [28]r e p o r t e dn o
relationship between viral load and presence of oral lesions.
The mean HIV viral load of patients having oral manifesta-
tions found in our study was 1,69,035copies/mL which was
higher as compared to other similar studies conducted in
Brazil {12,300copies/mm3} [24], Italy {17,900copies/mL}
[12], and South Africa {72,200copies/mL} [29], but much
lesser than a study conducted in Venezuela [9] where the
mean count was 15,102,00copies/mm3. These variations of
mean count for oral manifestations can be explained by
variations in sample size, ethnicity, use of ART, gender and
age distribution, and oral adverse habits.
EC was the most common ﬁnding in subpopu-
lation with HIV viral load with RNA copies greater
than 20,000copies/mL. A statistically signiﬁcant associ-
ation was observed between PC and high viral load
(>20,000copies/mL) (Table 6). Campo et al. [10], Margiotta
et al. [12], and Laurenco and Figueiredo [24] had also
found a positive correlation between high HIV viral loads
>10,000copies/mL and oral candidiasis. In our study no
correlation could be found between OHL and high viral
loads. This was in contrast to other studies where OHL
was associated to high HIV viral load [9, 24, 30]. Patton
et al. found that patients with OHL were twofold more
likely to have a higher viral load than people without oral
lesions [30], whereas Moura et al. had suggested OHL as
a clinical marker for HIV viral load >3000copies/µL[ 31].
Our ﬁnding of negative correlation for OHL should be
explored in future studies whether there is any diﬀerence in
relationshipbetweenOHLandhighviralloadsindeveloping
and developed nations.
The prevalence of oral manifestations of those patients
on antiretroviral therapy (ART) was comparatively lesser as
compared to patients not on ART (78.6% versus 82.0%;
P = .669), though diﬀerence was not statistically signiﬁcant
(Table 7). This ﬁnding was in concurrent with other studies
[32–34]. Among all oral manifestations, only melanotic
hyperpigmentation had a slightly higher prevalence in
patients on ART. This ﬁnding is similar to other studies
conducted in India [15, 34]. Various reasons that have been
attributed to increased oral pigmentation in patients with
ART are increased release of MSH caused by deregulation
of cytokines in HIV disease, smoking, Addison’s disease, and
use of melanocyte stimulating drugs like ART [34].
OHL can also be considered as a measure of eﬃcacy of
ART [12, 16]. There was a regressive, but not statistically
signiﬁcant, eﬀect of ART on OHL. Various studies have
documented a reduced prevalence of OHL in patients who
aretakingART[16,31,35].Thiscanbeattributedtoantiviral
eﬀect of ART. The Protease inhibitors, a class of ART, are also
known to exert anticandidal activity by inhibiting secreted
aspartyl proteinases [SAPs] secreted by candida species.
SAPs are the major virulence factors for candida species
and their inhibition would mean a reduced virulence and
hence decreased prevalence of oral candidiasis that has been
reported in various studies [36, 37]. The absence of Protease
inhibitors in our study sample could be the probable reason
why we could not observe a dramatic reduction in EC and
PC.
No oral warts were observed in our study. This ﬁnding
was similar to other studies conducted in Asia [14–16, 34].
The possible reason could be a functionally incomplete
reconstitution that might lead to development of human
papilloma virus-(HPV-) induced lesions like warts, condy-
lomas, and focal epithelial hyperplasia [38]. The probable
enhanced antiviral eﬀect of ART on HPV related to genetics
as well as the virulence factors could be the reasons for
absence of warts in Asian countries.
The presence of oral manifestations in patients on ART
may indicate advanced immune suppression or failure of
the therapy [34, 36]. Among subsample of HIV viral load
population (n − 30), 15 patients (50%) were on ART and
they had HIV viral load <20,000copies/mL (P<0.05). The
low number of patients with HIV viral loads on ART (n −
15) prevented the authors from doing meaningful statistical
analysis with individual oral manifestations. In our study we
could not ﬁnd any oral manifestation that could possibly
show signs of ART failure (P>. 05). A greater sample size
of patients on ART could be directed towards future research
for its association with oral manifestations.
HIV infection remains the deadliest disaster for human-
ity. Unfortunately, no eﬀective vaccine has been found
so far, and there is little hope that it will be developed
in near future which can combat the virus or at least
stimulate the host immune system. In this study, we found
a signiﬁcant association of CD4/CD8 ratio with EC but
not OHL. More studies are needed to carry out association
between oral manifestations and CD4/CD8 ratio, which isInternational Journal of Dentistry 7
a better laboratory marker than absolute CD4 count for
immune suppression. So far, studies have been conducted
only in western countries with almost scarcity of literature
in developing world. Studies similar to ours need to be
done with cohorts comprising of samples of resource-
constrainednations,whichcanbecomparedwiththosefrom
developed nations to evaluate if there are diﬀerences. Future
studies could be directed towards association between oral
manifestations and HIV viral load, a better marker of long-
term immune deterioration. A greater sample study size for
HIV viral load in developing nations will be required to
conﬁrm the ﬁndings in our study.
People infected with HIV need to be educated, inspired,
and empowered with knowledge so that they can protect
themselves from the impact of AIDS. To ensure a better care
and quality of life to these patients linkages with social sector
programmes for accessing social support to the patients,
recreational and skill development support, transport sub-
sidy to ensure ART care, and integrating nutritional support
within treatment regimens are certain strategies that can be
implemented. By regular intraoral examinations at frequent
intervals dentists can play a small but signiﬁcant role of
ensuring an eﬀective integrated delivery of health services
for HIV-infected patients. This can occur only if there
is joint action/strategy between health care providers and
various HIV-related government as well as nongovernment
organizations.
The possibility of an oral lesion index to predict HIV in
resource poor countries with no access to CD4 count or viral
load was suggested recently [39]. However to incorporate an
oral lesion index, certain regional parameters and research
studies that employ rigorous research methodologies with
emphasis on HIV viral load and CD4/CD8 ratio need to be
done. There is a need to compare the results of various cross-
sectional studies, and more longitudinal studies are required
in developing nations to formulate an oral lesion index that
can help as a marker for HIV-related immune suppression.
EC had good predictive values (84.5% and 85%) for
group I CD4/CD8 ratio <0.30. OHL is signiﬁcantly not
associated with low CD4/CD8 ratio. Patients having EC
were at 4 times risk of having CD4/CD8 ratio <0.30
as compared to patients with absence of EC. PC was
signiﬁcantly seen more frequently in patients with high viral
load >20,000copies/mL. There was reduced prevalence of
oral manifestations in patients on ART. More studies need
to be carried out, especially in Asia, for correlation of oral
manifestations with HIV viral load and CD4/CD8 ratio.
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